North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group

 
back
8 Malignant disease and immunosuppression

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

08-02-04 Other immunomodulating drugs

Axicabtagene ciloleucel Yescarta®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
 

Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
BCG bladder instillation
Formulary

Powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG.


Red  View SPC online
Daclizumab Zinbryta®
Restricted

Restriction: In line with NICE Guidance only

WITHDRAWN FROM MARKET

MHRA advice: Daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy (March 2018).

Link  EMA update on Daclizumab (Zinbryta)
Link  NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
 

Restricted Drug Red  View SPC online  HCD
Dimethyl fumarate Tecfidera®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Fingolimod Gilenya®
Formulary

Restriction: In line with NICE Guidance only

MHRA/CHM advice: Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy (April 2017)

MHRA/CHM advice: Fingolimod—not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013)

MHRA/CHM advice: Fingolimod: new contra-indications in relation to cardiac risk (December 2017)

MHRA/CHM advice: Fingolimod: updated advice about risk of cancers and serious infections (December 2017)

MHRA advice (Sep 2019): Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception

Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Glatiramer acetate Copaxone®
Formulary

Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006

Restriction: In line with NICE Guidance only

Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Interferon Alfa
Formulary
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
 

Red View adult BNF  View SPC online  View childrens BNF
Interferon Beta
Formulary

Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006

Restriction: In line with NICE Guidance only

Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Lenalidomide Revlimid®
Formulary

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
 

Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Lenalidomide plus Dexamethasone Revlimide®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Mifamurtide Mepact®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA235: Mifamurtide for the treatment of osteosarcoma
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Natalizumab Tysabri®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Peginterferon Alfa Pegasys®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
 

Red View adult BNF  View SPC online  View childrens BNF
Pomalidomide Imnovid®
Formulary

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

MHRA/CHM advice (May 2016): Risk of hepatitis B reactivation

Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
 

Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Rucaparib Rubraca®
Formulary

Restriction: In line with NICE guidance only

Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
 

Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Teriflunomide Aubagio®
Formulary

Restriction: In line with NICE Guidance only

Link  NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Thalidomide Celgene®
Formulary

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form.

Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
 

Red View adult BNF  View SPC online  View childrens BNF  HCD